ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: May 17, 2012

ClinicalTrials.gov ID: NCT00640562

Study Identification

Unique Protocol ID:	D1443L00031
Brief Title:	Quetiapine Extended Release Depression Symptoms (ExAttitude)
Official Title:	Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study
Secondary IDs:	

Study Status

Record Verification:	May 2012
Overall Status:	Completed
Study Start:	February 2008 []
Primary Completion:	February 2010 [Actual]
Study Completion:	February 2010 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	Sponsor
Collaborators:	

Oversight

U.S. FDA-regulated Drug:	

U.S. FDA-regulated Device:	
Unapproved/Uncleared Device:	No
IND/IDE Protocol:	No
Human Subjects Review:	Board Status: Approved Approval Number: 11/15/2007 Board Name: Comitato Etico per la Sperimentazione Clinica (Azienda USL n.12 Viareggio Board Affiliation: Comitato Etico per la Sperimentazione Clinica (Azienda USL n.12 Viareggio Phone: 0039 0584 6059408941 Email: cel@usl12.toscana.it
Data Monitoring:	No
Plan to Share IPD:	
FDA Regulated Intervention:	Yes
Section 801 Clinical Trial:	Yes

Study Description

Brief Summary:	Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Detailed Description:	

Conditions

Conditions:	Schizophrenia Depression
Keywords:	Schizophrenia Depression Quetiapine

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment

Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	No masking
Allocation:	Randomized
Enrollment:	216 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Quetiapine Extended Release	Drug: Quetiapine Extended Release Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day Other Names: • Seroquel XR™
Active Comparator: Risperidone	Drug: Risperidone Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient. Other Names: • Risperdal

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	65 Years

Sex: All

Gender Based:

Accepts Healthy Volunteers: No

Criteria: Inclusion Criteria:

- Provision of written informed consent
- Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR
- Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and HAM-D item 1 score ≥2

Exclusion Criteria:

- Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder
- Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period
- Use of Clozapine within 28 days prior to enrollment or Clozapine non responders
- Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug
- An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter
- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.

Contacts/Locations

Study Officials: Gino Montagnani, MD
Study Chair
AstraZeneca

Mario diFiorino
Study Principal Investigator
Ospedale Unico della Versilia (Lido di Camaiore, Lucca Italy)

Locations: Italy
Research Site
Fermo, AP, Italy

Research Site
Bergamo, BG, Italy

Research Site
Brindisi, BR, Italy

Research Site
Carbonia, CA, Italy

Research Site
Termoli, CB, Italy

Research Site
Catania, CT, Italy

Research Site
Nicosia, EN, Italy

Research Site
Lido Di Camaiore, LU, Italy

Research Site
Messina, ME, Italy

Research Site
Milazzo, ME, Italy

Research Site
Frattaminore, Italy

Research Site
Roma, Roma, Italy

Research Site
Nocera Inferiore, SA, Italy

Research Site
Vallo Della Lucania, SA, Italy

Research Site
Collegno, TO, Italy

Research Site
Aversa, CE, Italy

Research Site
Monza, MI, Italy

Research Site
La Spezia, SP, Italy

Research Site
Lecco, Italy

Research Site

Palermo, Italy

Research Site
Partinico, Italy

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	Adult male and female patients. with a diagnosis of schizophrenia or schizoaffective disorder (according to DSM-IVTR criteria). with depressive symptoms HAM-D baseline score ≥ 20. and HAM-D item 1 score ≥2.

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Overall Study

	Seroquel XR	Risperidone
Started	109	107
Completed	91	81
Not Completed	18	26

	Seroquel XR	Risperidone
Adverse Event	8	5
Lack of Efficacy	1	4
Protocol Violation	2	4
Withdrawal by Subject	6	10
Known risperidone intolerance	0	1
Past use of Seroquel - stopped due to AE	0	1
Low study drug dose	0	1
Glycosylated Hemoglobin >8	1	0

Baseline Characteristics

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Baseline Measures

		Seroquel XR	Risperidone	Total
Overall Number of Participants		107	103	210
Age, Continuous [1] Mean (Standard Deviation) Unit of measure: years	Number Analyzed	107 participants	103 participants	210 participants
		42.46 (10.71)	42.08 (11.48)	42.27 (11.10)
		[1] Measure Description: Number of participants is lower than number in Participants Flow module. 6 participants, 2 in Seroquel XR and 4 in Risperidone, were not valid for safety population because they did not assume any study drug administration.		
Sex: Female, Male Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	107 participants	103 participants	210 participants
	Female	51 47.66%	40 38.83%	91 43.33%
	Male	56 52.34%	63 61.17%	119 56.67%

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.
Measure Description	The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms. CDSS has 9 items rated on four–point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment. The sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression.
Time Frame	12 week from baseline to last visit

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score. Least Squares Mean (Standard Deviation) Unit of measure: Score on a scale	7.31 (6.1)	5.53 (6.4)

2. Secondary Outcome Measure:

Measure Title	Change From Baseline to Week 12 of HAM-D Score
Measure Description	21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline.
Time Frame	12 weeks from baseline to last visit

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Baseline to Week 12 of HAM-D Score Mean (Standard Deviation) Unit of measure: Score on scale	-29.83 (10.13)	-23.02 (10.33)

3. Secondary Outcome Measure:

Measure Title	Change From Baseline to Week 12 of PANSS Score
Measure Description	30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population.
Time Frame	12 weeks from baseline to last visit

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day

	Description
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Baseline to Week 12 of PANSS Score Mean (Standard Deviation) Unit of measure: score on scale	102.26 (24.14)	100.51 (25.65)

4. Secondary Outcome Measure:

Measure Title	- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score
Measure Description	The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates “normal, not at all ill”, while a score of 7 indicates “among the most extremely ill of patients”. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits
Time Frame	12 weeks from baseline to last visit

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score Least Squares Mean (Standard Deviation) Unit of measure: Score on scale	-1.50 (1.33)	-1.04 (1.31)

5. Secondary Outcome Measure:

Measure Title	CGI- Global Improvement Mean Score at Week 12
Measure Description	The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates “normal, not at all ill”, while a score of 7 indicates “among the most extremely ill of patients”. The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits
Time Frame	12week: descriptive statistic of CGI by visit and treatment

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103

	Seroquel XR	Risperidone
CGI- Global Improvement Mean Score at Week 12 Mean (Standard Deviation) Unit of measure: score on a scale	91 (4.47)	88 (4.55)

6. Secondary Outcome Measure:

Measure Title	Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score
Measure Description	These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or –1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response
Time Frame	12 week from baseline to last visit

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score Least Squares Mean (Standard Deviation) Unit of measure: score on scale	86.38 (4.12)	76.64 (4.70)

7. Secondary Outcome Measure:

Measure Title	Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section
Measure Description	Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline. The SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40 Change from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments.
Time Frame	12 weeks from baseline to last visit

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section Mean (Standard Deviation) Unit of measure: score on scale	2.74 (5.29)	3.88 (5.24)

8. Secondary Outcome Measure:

Measure Title	Concomitant Use of Antidepressive Drugs From Baseline to Week 12
Measure Description	Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration
Time Frame	12 week from baseline to last visi

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Concomitant Use of Antidepressive Drugs From Baseline to Week 12 Measure Type: Number Unit of measure: Participants	12	11

9. Secondary Outcome Measure:

Measure Title	Change From Screening Visit to Week 12 of Prolactin Live
Measure Description	Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit
Time Frame	12 week from screening visit to last visit

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Change From Screening Visit to Week 12 of Prolactin Live Least Squares Mean (Standard Deviation) Unit of measure: KG	61.20 (29.77)	90.80 (55.78)

10. Secondary Outcome Measure:

Measure Title	Body Mass Index (BMI) at Week 12
Measure Description	Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment.
Time Frame	12 week

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Body Mass Index (BMI) at Week 12 Mean (Standard Deviation) Unit of measure: Kg/m^2	29.07 (6.65)	28.80 (5.31)

11. Secondary Outcome Measure:

Measure Title	Concomitant Use of Antidepressive Drugs From Baseline to Week 12
Measure Description	Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration
Time Frame	Change of drug use from baseline to last visi

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day

	Description
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

Measured Values

	Seroquel XR	Risperidone
Overall Number of Participants Analyzed	107	103
Concomitant Use of Antidepressive Drugs From Baseline to Week 12 Measure Type: Number Unit of measure: Participants	14	17

Reported Adverse Events

Time Frame	[Not specified]
Adverse Event Reporting Description	[Not specified]

Reporting Groups

	Description
Seroquel XR	Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Risperidone	Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.

All-Cause Mortality

	Seroquel XR	Risperidone
	Affected/At Risk (%)	Affected/At Risk (%)
Total All-Cause Mortality	/	/

Serious Adverse Events

	Seroquel XR	Risperidone
	Affected/At Risk (%)	Affected/At Risk (%)
Total	4/109 (3.67%)	4/107 (3.74%)
Cardiac disorders		
Cardiocircolatory Arresti [A] †	1/109 (0.92%)	0/107 (0%)
Nervous system disorders		
Extrapiramidal Syndrome [A] †	0/109 (0%)	1/107 (0.93%)
Faint/Syndrome [A] †	1/109 (0.92%)	0/107 (0%)
Psychiatric disorders		
Acute Psycosis [A] †	1/109 (0.92%)	0/107 (0%)
Delusion [A] †	0/109 (0%)	1/107 (0.93%)
Disorientation [A] †	0/109 (0%)	1/107 (0.93%)
Psycotic Disorder [A] †	0/109 (0%)	1/107 (0.93%)
Respiratory, thoracic and mediastinal disorders		
Acute Respiratory Failure [A] †	1/109 (0.92%)	0/107 (0%)
Social circumstances		
Social Stay Hospitalisation [A] †	1/109 (0.92%)	0/107 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 10.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 0%

	Seroquel XR	Risperidone
	Affected/At Risk (%)	Affected/At Risk (%)
Total	28/	21/
Endocrine disorders		
Hyperprolactinemia [A] †	1/109 (0.92%)	10/107 (9.35%)
Gastrointestinal disorders		
Dry Months [A] †	5/109 (4.59%)	0/107 (0%)
General disorders		
Asthenia [A] †	3/109 (2.75%)	5/107 (4.67%)
Investigations		
Weight Increse [A] †	3/109 (2.75%)	2/107 (1.87%)
Nervous system disorders		
Sedation [A] †	5/109 (4.59%)	1/107 (0.93%)
Somnolence [A] †	6/109 (5.5%)	2/107 (1.87%)
Vascular disorders		
Hypotension [A] †	5/109 (4.59%)	1/107 (0.93%)

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA 10.0

Limitations and Caveats

Multicentre, randomized, open-label, flexible dose, parallel group, non inferiority

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.

Results Point of Contact:

Name/Official Title: Gerard Lynch

Organization: AstraZeneca

Phone:

Email: ClinicalTrialTransparency@astrazeneca.com